Transition in Sickle Cell Disease (SCD): A German Consensus Recommendation.
Germany
child blood non-malignant diseases
ethics issues and patient-oriented perspectives
patient registries and standardization
sickle cell disease (SCD)
transition
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
17 Jul 2022
17 Jul 2022
Historique:
received:
05
06
2022
revised:
26
06
2022
accepted:
12
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Sickle cell disease (SCD) is considered a rare disease in Germany. Due to the increasing prevalence, the acute and chronic morbidities associated with the disease and the sharp increase in the mortality rate of young adults, a need-based transition structure for patients with SCD in Germany is explicitly required. This is the first multicenter German consensus statement addressing the importance of implementing a standardized transition guideline that allows adolescents and young adults to safely transition from pediatric to adult care. Early identification of medical needs and intervention remains important in the context of chronic diseases. Effective measures can improve health care in general, as they lead to a reduction in disease and the consequential economic burden. It is noteworthy that improving structural barriers remains a key challenge even in highly developed countries such as Germany. Inclusion of these transition services for patients with SCD into the regular care of chronically ill adolescents and young adults should be ensured, as well as the coverage of costs associated with a structured transition process.
Identifiants
pubmed: 35887653
pii: jpm12071156
doi: 10.3390/jpm12071156
pmc: PMC9325299
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : DFG; grant FU356/12-1
Références
Curr Med Res Opin. 2021 May;37(5):761-768
pubmed: 33686891
Br J Haematol. 2018 Nov;183(4):648-660
pubmed: 30334577
J Clin Med. 2021 Sep 30;10(19):
pubmed: 34640578
N Engl J Med. 2017 Apr 20;376(16):1561-1573
pubmed: 28423290
J Adolesc Health. 1993 Nov;14(7):570-6
pubmed: 8312295
Qual Life Res. 2020 Jun;29(6):1533-1547
pubmed: 31933113
J Pediatr Nurs. 2018 Jan - Feb;38:122-126
pubmed: 28941954
J Genet Couns. 2021 Oct;30(5):1418-1427
pubmed: 33847032
Am J Occup Ther. 2015 Mar-Apr;69(2):6902350030p1-5
pubmed: 26122692
PLoS One. 2019 Aug 1;14(8):e0220116
pubmed: 31369582
BMC Health Serv Res. 2015 Dec 28;15:576
pubmed: 26711458
Fortschr Neurol Psychiatr. 2019 Nov;87(11):606-607
pubmed: 31756738
Health Qual Life Outcomes. 2014 Aug 22;12:125
pubmed: 25146160
Dtsch Arztebl Int. 2011 Aug;108(31-32):532-40
pubmed: 21886666
J Pediatr Nurs. 2017 Sep - Oct;36:191-196
pubmed: 28888502
Nat Rev Dis Primers. 2018 Mar 15;4:18010
pubmed: 29542687
BMJ Open. 2021 Nov 17;11(11):e050880
pubmed: 34789492
Pediatr Blood Cancer. 2016 Jan;63(1):168-70
pubmed: 26275168
Blood. 2018 Oct 25;132(17):1750-1760
pubmed: 30206116
Pediatr Blood Cancer. 2020 Apr;67(4):e28168
pubmed: 31904164
J Clin Transl Sci. 2018 Oct;2(5):334-342
pubmed: 30828476
Pediatr Blood Cancer. 2017 Jul;64(7):
pubmed: 28383793
Adv Ther. 2015 Apr;32(4):293-305
pubmed: 25832469
Child Adolesc Psychiatr Clin N Am. 2018 Jan;27(1):125-132
pubmed: 29157498
Int J Gen Med. 2020 Jul 07;13:361-377
pubmed: 32753936
Pediatr Blood Cancer. 2020 Apr;67(4):e28130
pubmed: 31867835
Chronic Illn. 2009 Dec;5(4):277-92
pubmed: 19933246
Dtsch Arztebl Int. 2010 Feb;107(5):65-71
pubmed: 20186311
Am J Hematol. 2011 Jan;86(1):116-20
pubmed: 21061308
J Clin Pathol. 2009 Jan;62(1):26-30
pubmed: 19103854
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):496-504
pubmed: 31808907
J Pediatr Hematol Oncol. 2014 Jul;36(5):389-94
pubmed: 24517960
Lancet Haematol. 2020 Apr;7(4):e329-e341
pubmed: 32220342